secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENvue Medical, Inc. (FEED)
CIK:        0001326706
Form:       8-K
Filed at:   2025-01-06T23:59:59+00:00
Accession:  0001493152-25-000385
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NanoVibronix completes UroShield pilot study; Nasdaq panel grants limited extension with conditions
--------------------------------------------------------------------------------

- Completed pilot phase of UroShield RCT at Univ. of Michigan; full trial to begin in 2025.
- Pilot focused on nursing home residents, studying reduction of UTIs, catheter blockages and pain.
- Nasdaq panel granted extension until March 31, 2025 to meet bid price and equity rules.
- Conditions: stockholder approval for reverse split by Feb 27, 2025; effect split and show $1.00 bid for 10 consecutive days.
- Must also demonstrate compliance with $2.5M stockholders' equity requirement; delisting risk remains.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326706/000149315225000385/0001493152-25-000385-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326706/000149315225000385/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-000385

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer